RA Medical Systems
Ra Medical Systems Inc. Receives Continued Listing Standard Notice from the NYSE
The written notice said Ra Medical is no longer in compliance with the NYSE’s continued listing standards as set forth in Section 802.01C of the NYSE’s Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.
Ra Medical Systems Receives FDA IDE Approval to Begin Pivotal Atherectomy Clinical Study
Ra Medical Systems reports in May 2017, DABRA received FDA 510(k) clearance for use in ablating a channel in occlusive peripheral vascular disease (PAD).
